Published in final edited form as:

Adv Biosyst. ; 2(5): . doi:10.1002/adbi.201800002.

Targeting and Modulation of Liver Myeloid Immune Cells by Hard-Shell Microbubbles

Klaudia T. Warzecha and Dr. Matthias Bartneck

Department of Medicine III, Medical Faculty, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Diana Möckel and Lia Appold

Department of Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany

Can Ergen

Department of Medicine III, Medical Faculty, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Dr. Wáel Al Rawashdeh and Dr. Felix Gremse

Department of Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany

Patricia M. Niemietz,

Department of Medicine III, Medical Faculty, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Dr. Willi Jahnen-Dechent, and

Helmholtz-Institute for Biomedical Engineering, Biointerface Laboratory, RWTH Aachen University, Medical Faculty, Aachen, Germany

Dr. Christian Trautwein

Department of Medicine III, Medical Faculty, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Dr. Fabian Kiessling and

Department of Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany

Dr. Twan Lammers

Department of Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceuticals, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

frank.tacke@gmx.net.

Conflict of Interest

FK is consultant of Bracco, shares IP on fluorescent PBCA-MB with FUJIFILM VisualSonics and is co-owner and advisor on the invivoContrast GmbH. The other authors disclose no conflict of interest.

Dr. Frank Tacke*

Department of Medicine III, Medical Faculty, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany

Abstract

Poly *n*-butylcyanoacrylate (PBCA)-based hard-shell microbubbles (MB) have manifold biomedical applications, including targeted drug delivery or contrast agents for ultrasound (US)-based liver imaging. MB and their fragments accumulate in phagocytes, especially in the liver, but it is unclear if MB affect the function of these immune cells. We herein show that human primary monocytes internalize different PBCA-MB by phagocytosis, which transiently inhibits monocyte migration in vertical chemotaxis assays and renders monocytes susceptible to cytotoxic effects of MB during US-guided destruction. Conversely, human macrophage viability and function, including cytokine release and polarization, remain unaffected after MB uptake. After i.v. injection in mice, MB predominantly accumulate in liver, especially in hepatic phagocytes (monocytes and Kupffer cells). Despite efficiently targeting myeloid immune cells in liver, MB or MB after US-elicited burst do not cause overt hepatotoxicity or inflammation. Furthermore, MB application with or without US-guided burst does not aggravate the course of experimental liver injury in mice or the inflammatory response to liver injury *in vivo*. In conclusion, PBCA-MB have immunomodulatory effects on primary human myeloid cells *in vitro*, but do not provoke hepatotoxicity, inflammation or altered response to liver injury *in vivo*, suggesting the safety of these MB for diagnostic and therapeutic purposes.

Keywords

microbubbles; ultrasound; cell migration; inflammation; macrophages; liver

1 Introduction

Microbubbles (MB) are gas-filled vesicles sizing from 1-5 μm with a shell composed of proteins, lipids (soft-shell MB) or polymers (hard-shell MB). They are routinely used as contrast agents in ultrasound (US) imaging, especially in liver imaging for diagnosing benign or malignant hepatic tumors.[1,2] The shell composition plays a pivotal role for circulation time, stability (physical and chemical), as well as for oscillation during US treatment. Imaging of flexible soft-shell MB is mostly done using non-destructive US, which is based on non-linear oscillation upon exposition to low- and medium intensity US pulses. Hard-shell MB such as those based on poly *n*-butylcyanoacrylate (PBCA) show less non-linear responses but higher backscattering properties, which can be of advantage for imaging at higher frequencies where the non-linear contrast modes are less effective.[3]

Although at present soft-shell MB are primarily used in clinical evaluation,[4] hard-shell MB might provide more diverse options for drug loading and multi-functionality because of their much thicker shell and the option of US-directed MB destruction allowing image-guided local drug release.[3,5] Additionally, hard-shell MB only exhibit a marginal complement activation (lower than soft-shell MB) underlining their biocompatibility.[6] Nevertheless, limited knowledge exists on the immunomodulatory effects of hard-shell MB

on the cellular and molecular level, especially in the context of US-mediated burst or in conditions of inflammatory diseases. We have recently shown that PBCA-MB and their fragments primarily end up in tissue macrophages, especially in the liver, upon systemic administration in mice.[7] Liver macrophages (phagocytes) are critical components to ensure homeostasis of the body, and they integrate danger or other environmental signals by inflammatory (often termed “M1”) or anti-inflammatory (often termed “M2”) responses.[8] In this respect, liver macrophages are key regulators of systemic inflammation and hepatic diseases.[9]

In this study, we set out experiments to assess the functional effects of hard-shell MB on monocytes/macrophages in general and liver macrophages in particular. We therefore investigated the impact of standard PBCA-MB, of PBCA-MB modified with streptavidin and of PBCA-MB functionalized with the bioactive tripeptide arginylglycylaspartic acid (RGD) on human monocytes and macrophages *in vitro*. Moreover, as the liver is routinely exposed to US procedures, we assessed the potential toxicity of MB in combination with US-guided destruction. Furthermore, we investigated the effects of fluorescently labeled MB on hepatic immune cells *in vivo* upon intravenous administration in healthy mice as well as in mice subjected to liver injury.

2 Results and Discussion

2.1 MB Accumulate in the Liver and are Cleared by Hepatic Monocytes and Macrophages

Gas-filled PBCA-MB were generated and fluorescently labeled (Figure S1A-B) in order to trace the fate of MB within the body in mice. The micro-sized constructs were i.v. injected into mice, and whole-body scans based on combined micro-computed tomography/fluorescence-mediated tomography (μ CT/FMT) were performed.[10] The anatomical μ CT data were used for an improved fluorescence reconstruction based on the accurate mouse shape and heterogeneous absorption and scattering maps (Figure 1A).[11] Organ segmentation was performed by delineating the organ boundaries in the μ CT images (Figure 1B).[12] Fluorescence quantification revealed that the liver rapidly and predominantly harbored 40% of the injected dose of MB shell constituents (Figure 1C). Half of the MB amount was still present in the liver after two hours. Most of the MB shell constituents were cleared from the body 24 hours after injection. Furthermore, we observed a delayed slight enrichment of MB shell constituents in spleen, but to a much lower extent than in liver (Figure 1C). Our data are well in accordance with a prior study using 2 μ m hard-shell MB, although these MB showed a slightly higher accumulation in spleen.[7] Similarly, an independent study using gamma-counting demonstrated that the highest MB concentrations were observed in liver and lung, the latter being probably related to temporary retention in the pulmonary arterial system.[13] Furthermore, this work, based on radioactively labelled PBCA MB of the same size and structure as in our current work, excluded that the fluorescent label accidentally detaches from the material. However, after two hours MB concentration in the lung was strongly decreased leading to a reincrease in blood circulation. [13] To investigate which cells among the different cells in the liver take up the injected dose of MB, we performed immunohistochemistry analyses (Figure 1D). MB are primarily found in Kupffer cells, the resident macrophages in the liver, characterized by high F4/80

expression, and to a lower extent in CD11b-expressing monocytes (or monocyte-derived macrophages), as shown by colocalization between MB and F4/80⁺ or CD11b⁺ cells (Figure 1D). In our study, low MB-related fluorescent signals were detected in other organs like spleen or lung, thus supporting that MB are predominantly enriched in the liver and cleared by the hepatic myeloid cells (monocytes and macrophages).

2.2 Myeloid Cell-specific Uptake Mechanisms of MB and Shell Fragments *in vitro*

Due to the fact that MB primarily accumulated in myeloid cells in the liver, we compared the cellular uptake efficiency of MB by human macrophages and monocytes *in vitro* using fluorescence microscopy and flow cytometric analysis. We studied the internalization of intact as well as fragmented MB by human primary macrophages and monocytes (Figure 2A-C, S2A) in comparison to human lymphocytes and granulocytes from peripheral blood (Figure S2B-C). We used a concentration of intact and fragmented MB of 4×10^6 per mL that reflects an *in vivo* concentration of 4×10^8 MB per kg body weight for targeted drug delivery.[14] Fluorescence microscopic analysis indicated that intact MB are rapidly fragmented either during or directly after internalization by human macrophages and monocytes, because incubated MB or MB-fragments showed the same morphology after internalization (Figure 2A). While an increase in the mean fluorescence intensity (MFI) demonstrating efficient uptake was noted for MB and fragments in macrophages, a clear increase in MFI of human monocytes was only detectable after MB incubation but not for fragments (Figure 2B-C, S2A). Furthermore, very few lymphocytes and a minor fraction of primary granulocytes internalized MB and/or their fragments (Figure S2B-C).

The incubation of primary human leukocytes with MB at 4°C instead of 37°C resulted in a suppression of MB internalization, indicating that the uptake is energy-dependent (Figure 2D).[15] To further investigate molecular mechanisms mediating the cell-specific uptake of MB, three important pathways for particle uptake,[16] namely receptor-mediated endocytosis, macropinocytosis or phagocytosis, were inhibited (Figure 2D). Monensin, a carboxylic ionophore that mediates proton movement across membranes, was used to block receptor-mediated endocytosis by entrapping receptor-ligand complexes.[17] Amiloride and its derivate 5-(N,N-Dimethyl)amiloride hydrochloride (DMA) block macropinocytosis, because they function as selective inhibitors of the sodium-hydrogen exchange pump in the plasma membrane affecting the intracellular pH.[18] To block phagocytosis, we used Cytochalasin D, an agent known to block polymerization of actin.[19] Treatment with Cytochalasin D, but not with Monensin or DMA, led to a significant decrease in the uptake of MB by human monocytes (Figure 2D). Phagocytosis as the prime uptake mechanisms was less clearly seen in the case of macrophages (although it has to be noted that these cells have a higher baseline MFI due to autofluorescence,[20] which may hampered the flow cytometry-based analysis). We excluded unspecific binding of complement proteins that might increase internalization efficiency of MB, by incubating cells in medium containing 5% human serum, instead of fetal calf serum (FCS), which is a source of complement protein (data not shown).

2.3 Transient Inhibition of Monocyte Migration by MB

We next tested consequences of MB internalization on the functional properties of human monocytes and macrophages. Interestingly, we noted that the adherence of human monocytes to cell culture plates was slightly reduced after internalization of MB, unlike if cells internalized 1 μ m sized latex beads (Lx beads, Figure 3A-B). This prompted us to study the potential impact of MB on immune cell migration, a key feature for the monocyte recruitment to inflammatory sites.[21] We determined the migration of human monocytes in response to functionalized MB in a transwell migration assay (“vertical cell migration”). Interestingly, spontaneous migration of monocytes was significantly inhibited by MB as well as by Mb⁺RGD at 60 minutes after treatment (Figure 3C). At this time-point, only few macrophages had migrated (Figure S3A). After 16 hours, migration of monocytes was increased compared to 1 hour, but not substantially affected by MB (Figure 3C). We also tested horizontal migration of human immune cells *in vitro* based on a scratch assay (performed on a confluent cell monolayer aiming to better mimic migration of cells *in vivo*) (Figure 3D-E). Monocytes were incubated with MB using the conditions described before, and migration towards the cell-free gap was examined by analyzing micrographs taken up to 24 hours after scratch (Figure 3E). 60 minutes after scratching, twice as many monocytes migrated compared to macrophages (Figure S3B), illustrating their higher motility. Independent of the designated time-points, the treatment with regular or functionalized MB did not affect horizontal migration of monocytes (Figure 3D). We observed that the internalization of MB affected human monocytes by inhibiting their spontaneous migration, at least temporarily, without influencing viability. Next, we determined whether cytokine release as an additional functional property was altered after MB treatment. Macrophages were incubated with MB, soluble biotinylated RGD (2 nM/mL), MB functionalized with RGD or lipopolysaccharide (LPS, 1 μ g/mL) for 24 hours. Protein release of different pro- or anti-inflammatory cytokines remained unaffected by MB, whereas LPS that served as a positive control strongly induced inflammatory cytokines such as interleukin 1 β (IL-1 β) or tumor necrosis factor (TNF) (Figure 3F). Furthermore, functionalization of MB did not change cell morphology (Figure S3C) and did not alter surface expression level of anti-myeloid related protein 8/14 (MRP8/14) and CD163, respectively,[22] as well as of MHC-II molecules (HLA-DR) (Figure S3D). Although it was described before that the bioactive tripeptide RGD induced pronounced inflammatory conditions of human primary macrophages once coupled to a surface,[23] functionalization of MB by RGD did not induce inflammatory properties of the cells. In accordance with other studies, we used a relatively low concentration of soluble RGD, which had no activating effect on human macrophages by itself.[24]

2.4 Cytotoxic Effects on Myeloid Cells during US-provoked MB Disruption

We next analyzed the potential impact of MB uptake on the viability of human immune cell populations 24 hours after MB incubation with two different concentrations (4×10^5 and 4×10^6 MB *per* mL). The viability of human monocytes remained unaffected by MB; ethanol was used as a positive control for promoting cell death (Figure 4A-B). We next tested if the uptake of MB by human cells regularly results in MB fragmentation. We therefore exposed human immune cells to US *in vitro* directly following MB uptake (Figure 4C). We hypothesized that those cells that have still incorporated intact MB should be susceptible to

US-mediated MB burst and subsequent cell toxicity. Indeed, a part of MB remained intact after internalization by monocytes, because US-guided destruction triggered cell death of monocytes (Figure 4D-E, S4). In contrast, the viability of mature human macrophages was not affected under identical experimental settings. To destroy hard-shell MB in this experimental setting, an US pulse with an acoustic pressure of MI of 0.9 was applied resulting in an efficient destruction of the polymer-based MB (Figure 4C). It was reported earlier that the destruction of MB by high-intensity US can provoke cell-specific effects. For instance, in a prior study, soft-shell MB remained intact after phagocytosis by neutrophils or monocytes and remained susceptible to US disruption, thereby affecting cell viability of neutrophils and monocytes.[25] In contrast, macrophages in our study were not affected by US-guided MB burst, which could be related to cell-intrinsic features of macrophages, a more terminally differentiated cell compared to monocytes or neutrophils,[26] to the intracellular compartment in which MB are localized after phagocytosis or to the fact that MB are completely fragmented after internalization by human macrophages.

2.5 Evaluation of Hepatotoxic and Inflammatory Effects of MB *in vivo*

The internalization of the micro-sized particles by human monocytes *in vitro* was accompanied by significantly increased cytotoxicity upon US treatment (Figure 4). To reveal whether these observations translate into US-mediated toxicity *in vivo*, we performed liver US of mice that had been injected with MB. As evidenced by US using brightness modulation (B mode) as well as contrast mode, MB and their fragments accumulated in the liver within minutes after injection (Figure 5A-B). We conducted a US-guided destructive pulse seven minutes after injection to destroy intact MB that had been attached to or internalized by hepatic phagocytes. The vast majority of MB was disrupted using a high-frequency destructive pulse illustrated by the mean intensity power (Figure 5C). After the first destructive pulse, no further accumulation of MB was observed, showing that most of the MB were rapidly and efficiently cleared from the circulation before the first destructive pulse. Importantly, neither MB nor Mb⁺US treatment induced any type of overt liver damage, as analyzed by histology (Figure 5D) or the serum liver injury indicator alanine aminotransferase (ALT, Figure 5E). These findings were further supported by flow cytometric analysis of hepatic leukocytes, which did not change upon treatment (Figure 5F). Interestingly, monocyte-derived macrophages, which internalized MB and their fragments, as well as hepatic neutrophils (a sensitive indicator of liver injury), were unaffected upon MB treatment and in combination with US (Figure 5G). Similar results were obtained by flow cytometric analysis for blood cells (data not shown).

2.6 Analysis of Immunomodulatory Functions of MB and MB Burst during Liver Injury

These data demonstrated that MB or Mb⁺US did not affect hepatic immune cells in homeostasis. However, we wanted to rule out that their functionality was altered in conditions of liver injury. Therefore, mice that had been exposed to MB with or without US treatment were challenged with an i.p. injection of carbon tetrachloride (CCl₄), which induces a severe toxic liver damage, to examine whether MB impaired immune cells to react efficiently to liver injury (Figure 6A). This experiment revealed no overtly increased liver injury by histology (Figure 6B) or ALT levels (Figure 6C). Moreover, hepatic leukocytes (Figure 6D) and inflammatory macrophages or neutrophils (Figure 6E) remained unaffected

by prior MB and US treatment, suggesting that injury-mediated cell recruitment is not impaired by MB and shell constituents.

We next examined whether MB delivery and US burst during ongoing liver injury would affect liver damage or inflammation. Therefore, mice were treated with CCl₄ to induce severe acute liver damage, followed by MB and US treatment at 12 hours, when substantial injury is established (Figure 6F). MB treatment during progressive liver damage did not change overt liver injury as shown by histology (Figure 6G) and serum ALT (Figure 6H). Moreover, the recruitment of inflammatory cells (Figure 6I), including macrophages and neutrophils (Figure 6J), to the liver remained unaffected.

We believe that our data have important implications for the future development of hard-shell MB as drug carriers. Among many nano- and micro-sized carrier structures, there is the concern that either the material or the functionalization part might have additional, unwanted side effects on the immune system, especially in their prime target organ liver. This has been exemplarily demonstrated for gold nanorods, which affect the polarization of macrophages that internalize the rods,[27] or for selectin-mimicking polymers that affect the migration of macrophages.[28] Hard-shell MB offer the possibility for a targeting of phagocytes in solid organs,[7] and drug release from MB could even be tailored to distinct sites such as tumor tissue by US-guided disruption.[29] Although MB affect monocyte viability and migration *in vitro*, which had been previously demonstrated for soft-shell MB as well,[30] they do not impair the viability or functionality of hepatic myeloid cells *in vivo*, which represent their main cellular targets after systemic administration. Nonetheless, long(er) term and repetitive exposure need to be tested in future studies in order to confirm the favorable safety profile. Moreover, our study used primary human monocytes and macrophages *in vitro* side-by-side to extensive *in vivo* studies in healthy and diseased mice. While these data consistently support the immunological safety of hard-shell MB, it cannot be excluded that murine and human immune cells, particularly in human liver, might show different responses. Thus, further in-depth analyses with human liver cells are warranted.

3 Conclusion

In this study, we comprehensively analyzed the immunological properties of MB, which were non-functionalized or surface-functionalized using Rhodamine-B, streptavidin and RGD, on two different biological systems: murine hepatic immune cells and human primary leukocytes. Our data demonstrate that MB exerted no activating effect on human macrophages *in vitro*. Interestingly, human myeloid cells showed different potential for uptake and migration of hard-shell MB shell constituents. Monocytes internalized MB by phagocytosis, which transiently inhibited their migratory properties, and were modestly susceptible to the cytotoxic effects of MB during US-guided destruction. On the other hand, human macrophage viability and function remained unaffected after MB uptake. After i.v. injection in mice, MB preferentially accumulated in liver. Although MB were suitable to target immune cells in the liver, they did not cause overt hepatotoxicity, did not alter immune cell function and did not affect the inflammatory response to acute liver injury. Therefore, our data strongly support the further development of MB for multiple diagnostic, therapeutic and theranostic applications, possibly also for the treatment of liver diseases or cancer.

Combining MB that incorporate drugs and US-mediated MB disruption may provide options for targeted drug delivery without strong immunological bystander effects.

4 Experimental Section

Microbubble Preparation

The preparation of PBCA-MB by emulsion polymerization techniques was described before. [13] PBCA-MB were washed four times by flotation to remove untrapped polymer. Fluorescently labeled MB were additionally prepared based on a one-step drug-loading procedure. Therefore, Rhodamine-B (AppliChem, Germany), which was dissolved in water, or 1,1,3,3,3-Hexamethylindotricarbocyanine (HITC) iodide (the higher wavelength (absorption max. 740 nm, emission max. 780 nm), which was required for the *in vivo* biodistribution studies, was added during the polymerization process. MB were washed by flotation and their size and concentration were investigated by using a Multisizer 3 (Beckmann Coulter, Germany). Modified MB were prepared by coupling streptavidin (Merck, Germany) to the surface of a 10% hydrolysis of MB. Therefore, MB and fluorescently labeled MB were first treated with 0.1N NaOH to introduce carboxyl groups and then 5×10^8 MB were dissolved in 10 mM sodium acetate (pH 4.5), incubated with 7.5 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Merck, Germany) and 300 μ g streptavidin for 60 minutes at room temperature and stirred overnight at 4°C. To produce MB functionalized with streptavidin and RGD, 2 nM/mL of biotinylated RGD was added to MB coupled to streptavidin and incubated for five minutes until biotin and streptavidin built a strong complex. MB were fragmented using an ultrasonic cleaner (UCS 200TH, VWR, USA) by sonicating 1 mL of the MB for 1 minute at 60 W. The mean fragment size was 243 nm (compared to intact MB with a mean size of 1-3 μ m). The concentration of the fragmented MB was $1.93 \times 10^{13} \pm 0.53 \times 10^{13}$ particles *per* mL.

Human Cells

Human primary blood leukocytes including granulocytes, lymphocytes and monocytes were retrieved from healthy volunteers using dextran sedimentation. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-based density gradient centrifugation as described before.[31] After centrifugation, PBMC were incubated at 37 °C for 30 minutes on bacterial grade petri dishes at a density of 2.5 million cells *per* mL in cell culture medium (RPMI1640, PAA, Austria) with 1.5 % heat-inactivated autologous serum, sterile-filtered using a 0.2 μ m filter (Corning, USA) in a humidified incubator with 5 % CO₂. Human monocytes become adherent, while lymphocytes remain in the supernatant. After removing the supernatant and washing with 37°C RPMI1640, the monocytes were cultured for further seven days in RPMI1640 containing 5 % autologous serum to obtain macrophages. Afterwards, the adherent macrophages were put on ice for 20 minutes and then detached using a cell scraper (SPL, Korea). For the human *in vitro* experiments, 4×10^6 MB *per* mL medium were used that reflects an *in vivo* concentration of 4×10^8 MB *per* kg body weight based on the assumption that one mouse has a total body fluid volume of 2.5 mL. Informed signed consents were obtained from all healthy volunteers.

Mice

C57BL/6J wild-type and hairless Balb/c nu/nu mice (used for μ CT/FMT experiments) were housed in a specific pathogen-free environment. All experiments were done with male animals at the age of eight weeks that were carried out according to the guidelines of the federation of laboratory animal science associations (FELASA). For the *in vivo* studies, 4×10^8 MB *per* kg body weight were injected intravenously via the tail vein, based on earlier data on the targeted and triggered drug-delivery using polymer-based MB.[14] This dose equates to approximately 80 μ g PBCA (as assessed by weighing the dried mass after washing) *per* kg body weight (i.e. 2 μ g PBCA *per* animal).

μ CT/FMT Imaging

Balb/c nu/nu mice were injected intravenously with fluorescently labeled MB. A whole body-scan was performed using μ CT scanning (Tomoscope Duo, CT Imaging Germany) followed by FMT imaging (FMT2500 LX, PerkinElmer, USA) as described earlier.[10] The total fluorescence intensity was evaluated by normalization to the total fluorescence intensity in the whole mouse 15 minutes after MB injection.

Staining of Liver Sections

Formalin-embedded liver sections were cut into 10 μ m pieces, dried at RT for 2 hours and washed three times with phosphate-buffered saline (PBS, PAA, Austria). Liver sections were stained with directly conjugated rat anti-mouse F4/80 and CD11b (both BD, Germany) in a moist chamber overnight. Samples were washed three times for 5 minutes with PBS and mounted on cover slips using Vectashield mounting medium (Vector laboratories, USA). The fluorescently labeled MB (yellow), Kupffer cells (F4/80⁺, red), monocyte-derived macrophages (CD11b⁺, green) and cell nuclei (blue) were detected using an Axio Imager M2 (Zeiss, Germany).

Flow Cytometry

For human macrophages, cell surface markers were stained with directly conjugated mouse anti-human antibodies MRP8/14 (BMA biomedical, Switzerland), anti-CD163 (R&D systems, USA) and anti-HLA-DR (BD, Germany). For mouse experiments, hepatic leukocytes were isolated and stained for flow cytometry as described earlier.[27] Cell suspensions were filtered using a 100 μ m mesh. To count cells, 2×10^4 counting beads (calibrate beads, BD, Germany) were added to all samples. Flow cytometric data are given as MFI. Human blood cell populations are represented in absolute numbers or as percentages of leukocytes. Murine cell populations are shown in absolute numbers calculated from organ weight or as percentages of leukocytes. Using this methodology for calculation, a healthy mouse liver (~2 g) contains approximately 1.25 million Kupffer cells.

Uptake Studies and Microscopy

Human monocytes (two million cells *per* mL) and macrophages (one million cells *per* mL) were incubated for 60 minutes with fluorescently labeled MB (4×10^6 *per* mL) in RPMI1640 and 5 % FCS (PAA, Austria) at 37°C or 4°C under continuous shaking conditions (500rpm) in 1.5 mL tubes on a Thermomixer comfort (Eppendorf, Germany). For studies of the uptake

mechanism, the cells were incubated with the inhibitors Monensin (100 µg/mL), DMA (50 µM), or Cytochalasin D (40 µM, all from Merck, Germany) for 30 minutes prior to uptake analysis. The cells were washed with PBS and counted using a FACS Canto II (BD, Germany). Data were analyzed using FlowJo (TreeStar, USA). For plasma membrane and nuclear staining, human monocytes and macrophages were first subjected to an uptake study with fluorescently labeled MB. They were put on glass slides coated with poly-L-lysine (Merck, Germany). Adherent cells were treated with a mix of 5 µg/mL wheat germ agglutinin (WGA) Alexa Fluor-488 conjugate (Invitrogen, UK) and 100 ng/mL 4',6-diamidino-2-phenylindole (DAPI, invitrogen, UK) for 30 minutes. They were washed three times with Hank's balanced salt solution (HBSS, PAA, Austria) and mounted on cover slips using Vectashield mounting medium (Vector laboratories, USA). The fluorescently labeled MB (red channel) and labeled cells (green and blue channel) were detected using an Axio Imager M2 (Zeiss, Germany).

Migration Studies and Time Lapse Microscopy

Human macrophages and monocytes were incubated with MB to allow MB uptake. Afterwards, two million monocytes or one million macrophages were resolved in 200 µl RPMI1640 with 1 % FCS and added on top of a transwell insert (Millipore, USA) that was inserted on a 24-well plate (Greiner, Austria) containing 800 µl of RPMI1640 and 1 % FCS at the bottom. Cells migration was studied after 60 minutes or 16 hours after incubation at 37°C. Cells that migrated to the bottom of the 24-well plate were counted by flow cytometry. To analyze horizontal cell migration behavior into a defined area, we performed an experiment similar to a "scratch" assay using silicone inserts for self-insertion (ibidi, Germany). To this end, human monocytes and macrophages were treated with functionalized MB for 24 hours, washed with PBS, and resolved in 1 mL RPMI1640 with 1.5 % autologous serum on 24-well plates containing the culture inserts. Once the cells became adherent, the inserts were removed resulting in a cell layer with a 500 µm cell-free gap. Using an Axio Observer Z1 equipped with an Axio Cam MR and an XLMulti S1 DARK LS incubator (Zeiss, Germany), micrographs of migrating cells were taken at the designated time-points. The data were processed with the ZEN pro.2012 software (Zeiss, Germany). Video sequence analysis was performed using Imaris (version 7.7.2, Switzerland) and ilastik software (version 1.1.2, Germany).

Cytokine Release

The release of different cytokines by human macrophages into the cell culture medium was quantified using a bead-based multiplex assay (ThermoFisher, USA). All results are based on the comparison to the untreated control. 1 µg/mL LPS (Merck, Germany) served as a control.

In vitro Ultrasound and Cell Viability Assessment

Human monocytes and macrophages were incubated with MB in RPMI1640 and 5 % FCS for 60 minutes and transferred to a solidified matrix of 10 % gelatin including 1 mL inlets to insert the medium containing cells. The solidified gelatin is required to ensure an optimal transmission during US treatment. US imaging was performed using a preclinical US device (Vevo 2100, VisualSonics, Canada) with an MS250 transducer (VisualSonics, Canada). MB

were destroyed by applying destructive US at a frequency of 16 MHz with an MI of 0.9 (corresponding to 100 % power). Afterwards, cells were taken out of the inlets, washed with PBS and transferred to 24-well plates. Live/dead staining including calcein-acetoxymethyl for staining of viable cells and propidium-iodide for labeling dead cells was done according to the instructions of the manufacturer (Life Technologies, USA). Data processing was performed using ilastik software (version 1.1.2, Germany).

Liver Injury Model

4×10^8 MB *per* kg body weight were injected intravenously at a volume of 125 μ L in eight weeks old c57BL/6 mice. Acute liver injury was induced by intraperitoneal injection of 0.6 mL/kg CCl₄ (Merck, Germany) 24 hours before euthanizing mice.

In vivo Ultrasound

Mice were anesthetized using isoflurane and hair was removed at the abdomen before performing US imaging using the Vevo2100 system with the MS250 transducer. We focused on the liver in B mode- US imaging and injected 10^7 MB intravenously that directly enriched in the liver. A first destructive pulse at a frequency of 18 MHz with an MI of 0.7 (corresponding to 100 % power) was induced after seven minutes to destroy MB in the liver, resulting in a decreased signal of contrast mean power. This was followed by a continuous imaging with an MI of 0.03 (corresponding to 4 % power) for five minutes and a second destructive pulse at 100 % power to ensure that all MB were destroyed in the liver during the first destructive pulse.

Statistical Analysis

Data presented as mean $\pm$ SD, n = 3. All outliers were included in the analyses. P-values are calculated using two-tailed unpaired Student *t*-test. Significance was defined as **p*<0.05, ***p*<0.01, ****p*<0.001. Statistical analysis was carried out using GraphPad prism 5.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was funded by the German Research Foundation (Ta434/3-1, Ta434/5-1, SFB/TRR57 P09 to FT), by the START program of the Medical Faculty of the RWTH Aachen University (to MB), by the Wilhelm Sander Foundation (to MB) and by ERC StG-309495 (to TL). The authors gratefully acknowledge Dr. S. Fokong for assistance with microbubble preparation and characterization, Dr. J. Ehling and A. Rix for excellent guidance during ultrasound treatment.

References

- [1]. Klibanov AL, Hossack JA. Invest Radiol. 2015; 50:657. [PubMed: 26200224]
- [2]. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, et al. Ultrasound Med Biol. 2013; 39:187. World Federation for Ultrasound in, U. European Federation of Societies for. [PubMed: 23137926]
- [3]. Koczera P, Appold L, Shi Y, Liu M, Dasgupta A, Pathak V, Ojha T, Fokong S, Wu Z, van Zandvoort M, Iranzo O, et al. J Control Release. 2017; 259:128. [PubMed: 28279799]

- [4]. Wijkstra, H. [accessed Sept 2017] BR55 in prostate cancer: an exploratory clinical trial. 2013. <<https://clinicaltrials.gov/ct2/show/NCT01253213>>
- [5]. Blum NT, Yildirim A, Chattaraj R, Goodwin AP. *Theranostics*. 2017; 7:694. [PubMed: 28255360]
- [6]. Rix A, Fokong S, Heringer S, Pjontek R, Kabelitz L, Theek B, Brockmann MA, Wiesmann M, Kiessling F. *Invest Radiol*. 2016; 51:767. [PubMed: 27119438]
- [7]. Ergen C, Heymann F, Al Rawashdeh W, Gremse F, Bartneck M, Panzer U, Pola R, Pechar M, Storm G, Mohr N, Barz M, et al. *Biomaterials*. 2017; 114:106. [PubMed: 27855336]
- [8]. Mowat AM, Scott CL, Bain CC. *Nat Med*. 2017; 23:1258. [PubMed: 29117177]
- [9]. Krenkel O, Tacke F. *Nat Rev Immunol*. 2017; 17:306. [PubMed: 28317925]
- [10]. Gremse F, Doleschel D, Zafarnia S, Babler A, Jahnke-Dechent W, Lammers T, Lederle W, Kiessling F. *J Vis Exp*. 2015:e52770. [PubMed: 26066033]
- [11]. Gremse F, Theek B, Kunjachan S, Lederle W, Pardo A, Barth S, Lammers T, Naumann U, Kiessling F. *Theranostics*. 2014; 4:960. [PubMed: 25157277]
- [12]. Gremse F, Stark M, Ehling J, Menzel JR, Lammers T, Kiessling F. *Theranostics*. 2016; 6:328. [PubMed: 26909109]
- [13]. Palmowski M, Morgenstern B, Hauff P, Reinhardt M, Huppert J, Maurer M, Woenne EC, Doerk S, Ladewig G, Jenne JW, Delorme S, et al. *Invest Radiol*. 2008; 43:162. [PubMed: 18301312]
- [14]. Fokong S, Theek B, Wu Z, Koczera P, Appold L, Jorge S, Resch-Genger U, van Zandvoort M, Storm G, Kiessling F, Lammers T. *J Control Release*. 2012; 163:75. [PubMed: 22580225]
- [15]. Bartneck M, Keul HA, Singh S, Czaja K, Bornemann J, Bockstaller M, Moeller M, Zwadlo-Klarwasser G, Groll J. *ACS Nano*. 2010; 4:3073. [PubMed: 20507158]
- [16]. Dobrovolskaia MA, McNeil SE. *Nat Nanotechnol*. 2007; 2:469. [PubMed: 18654343]
- [17]. Wileman T, Boshans RL, Schlesinger P, Stahl P. *Biochem J*. 1984; 220:665. [PubMed: 6087792]
- [18]. Sandgren KJ, Wilkinson J, Miranda-Saksena M, McInerney GM, Byth-Wilson K, Robinson PJ, Cunningham AL. *PLoS Pathog*. 2010; 6:e1000866. [PubMed: 20421949]
- [19]. Conner SD, Schmid SL. *Nature*. 2003; 422:37. [PubMed: 12621426]
- [20]. Bartneck M, Scheyda KM, Warzecha KT, Rizzo LY, Hittatiya K, Luedde T, Storm G, Trautwein C, Lammers T, Tacke F. *Biomaterials*. 2015; 37:367. [PubMed: 25453965]
- [21]. Heymann F, Tacke F. *Nat Rev Gastroenterol Hepatol*. 2016; 13:88. [PubMed: 26758786]
- [22]. Gratchev A, Kzhyskowska J, Utikal J, Goerdts S. *Scand J Immunol*. 2005; 61:10. [PubMed: 15644118]
- [23]. Bartneck M, Skazik C, Paul NE, Salber J, Klee D, Zwadlo-Klarwasser G. *Macromol Biosci*. 2014; 14:411. [PubMed: 24821669]
- [24]. Moon C, Han JR, Park HJ, Hah JS, Kang JL. *Respir Res*. 2009; 10:18. [PubMed: 19272161]
- [25]. Lindner JR, Dayton PA, Coggins MP, Ley K, Song J, Ferrara K, Kaul S. *Circulation*. 2000; 102:531. [PubMed: 10920065]
- [26]. Varol C, Mildner A, Jung S. *Annu Rev Immunol*. 2015; 33:643. [PubMed: 25861979]
- [27]. Bartneck M, Ritz T, Keul HA, Wambach M, Bornemann J, Gbureck U, Ehling J, Lammers T, Heymann F, Gassler N, Ludde T, et al. *ACS Nano*. 2012; 6:8767. [PubMed: 22994679]
- [28]. Moog KE, Barz M, Bartneck M, Beceren-Braun F, Mohr N, Wu Z, Braun L, Dervede J, Liehn EA, Tacke F, Lammers T, et al. *Angew Chem Int Ed Engl*. 2017; 56:1416. [PubMed: 28005299]
- [29]. Eggen S, Fagerland SM, Morch Y, Hansen R, Sovik K, Berg S, Furu H, Bohn AD, Lilledahl MB, Angelsen A, Angelsen B, et al. *J Control Release*. 2014; 187:39. [PubMed: 24852099]
- [30]. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR. *Circulation*. 2007; 116:276. [PubMed: 17592078]
- [31]. Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C, Lammers T, Tacke F. *Nanomedicine*. 2014; 10:1209. [PubMed: 24607939]

Figure 1.

Microbubble (MB) distribution *in vivo*. 4×10^8 fluorescently labeled polymeric *n*-butyl cyanoacrylate (PBCA)-MB *per* kg body weight were injected intravenously into eight weeks old mice. (A) Whole body scans generated using micro computed tomography (μ CT)/fluorescence-mediated tomography (FMT) imaging, representative images show uptake in liver and spleen. (B) μ CT images with organ segmentation showing liver (in red) and spleen (in green). (C) Percentage of injected dose assessed by CT/FMT shown for liver and spleen. $n=3$ mice. (D) Immunofluorescence images of liver sections showing co-localization between

MB (yellow) and Kupffer cells (F4/80, red) or monocyte-derived macrophages (CD11b, green). Cell nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI, blue).

Figure 2.

Uptake of fluorescent microbubbles (MB) by primary human myeloid immune cells. (A) Representative images of cell type specific uptake of fluorescently labeled MB by human macrophages and monocytes. Cells were incubated for 60 minutes with MB (4×10^6 per mL, red, arrows), cell membranes were stained with wheat germ agglutinin (WGA-488, green) and nuclei using 4',6-diamidino-2-phenylindole (DAPI, blue). Uptake of fluorescently labeled MB by human blood cells and macrophages studied after 60 minutes of incubation by flow cytometry based on (B) quantification and (C) mean fluorescence intensity (MFI). (D) Investigation of the uptake mechanism by incubating immune cells with fluorescently

labeled MB at 4°C or by using inhibitors of endocytosis (Monensin), macropinocytosis (5-(*N,N*-Dimethyl)amiloride hydrochloride (DMA), and phagocytosis (Cytochalasin D) 30 minutes prior to the incubation with fluorescently labeled MB at 37°C. Data represent mean $\pm$ SD ($n=6$ *per* condition); * $P<0.05$, ** $P<0.01$, *** $P<0.001$ (two-tailed unpaired Student *t*-test).

Figure 3.

Influence of microbubbles (MB) on functional properties of monocytes. (A) Human monocytes treated with MB (4×10^6 per mL), or Latex (Lx) Beads. Nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI, blue) and (B) quantification of living adherent cells. (C) Monocytes were incubated with MB, RGD (5 pmol) or a combination of MB functionalized with RGD for 60 minutes. Vertical migration of human monocytes for 60 minutes or 16 hours. Statistical summary based on cell numbers by flow cytometry. (D) Horizontal migration of human monocytes for 60 minutes, twelve hours, or 24 hours. Flow

cytometric analyses based on cell numbers and (E) representative images using scratch assay analyses. (F) Monocytes were incubated with MB, RGD, a combination of MB functionalized with RGD or lipopolysaccharides (LPS, 1 $\mu\text{g}/\text{mL}$) for 24 hours. Cytokine release by human macrophages. Data represent mean $\pm$ SD ($n = 4$ per condition); * $P < 0.05$, ** $P < 0.01$ (two-tailed unpaired Student t -test).

Figure 4.

Cell type-specific cytotoxic effects of microbubbles (MB) on human myeloid immune cells. (A) Human monocytes incubated with different concentrations of MB for 24 hours, untreated (control), or incubated for five minutes with 70 % EtOH (positive control). Viable cells are stained with calcein-acetoxymethyl (green) and dead cells with propidium iodide (red). (B) Statistical quantification of the live/dead staining using different concentrations of MB based on the percentage of untreated living cells. (C) Macrophages and monocytes treated with MB (4×10^6 per mL) for 24 hours and then embedded into 10 % gelatin. Human cells with internalized MB (appear white) were exposed to an ultrasound (US)-guided burst of MB (red dots) for five minutes or remained untreated. (D) Quantification of the live/dead staining after US-guided burst using percentage of living untreated cells. (E) Live/dead staining of viable (green) or dead (red) cells after US-guided burst (+US) or without burst (-

US). Data represent mean $\pm$ SD ($n=6$ *per* condition); * $P<0.05$, ** $P<0.01$, *** $P<0.001$ (two-tailed unpaired Student *t*-test).

Figure 5.

Effects of microbubble (MB) disruption on liver homeostasis *in vivo*. Eight weeks old C57BL/6 mice were injected intravenously with 4×10^8 fluorescently labeled MB *per kg* body weight or remained untreated. Mice were exposed to an ultrasound (US)-guided burst of MB (+US) or remained untreated (-US). After 24 hours mice were sacrificed. (A) US-based imaging of murine liver. Two-dimensional US image display using brightness modulation (B mode) and (B) contrast mode during injection of MB (highlighted in purple circles) and after burst of MB (highlighted in red circles). (C) Representative images of the mean contrast intensity (signal intensity) of MB during injection and after US-guided burst. (D) Representative images of hematoxylin and eosin (H&E) staining of liver sections and (E) serum levels of alanine aminotransferase (ALT) activity after exposition to a US-guided burst of MB (+US, black) or without (-US, white). (F) Flow cytometric quantification of

leukocyte cell number and (G) flow cytometry-based quantification of inflammatory macrophages and neutrophils in the liver. Data represent mean $\pm$ SD ($n=3$ *per* condition), two-tailed unpaired Student *t*-test.

Figure 6.

Effects of microbubbles (MB) on experimental liver injury *in vivo*. (A) Eight weeks old C57BL/6 mice remained untreated or were injected intravenously with 4×10^8 fluorescently labeled MB *per kg* body weight followed by an ultrasound (US)-guided burst of MB after seven minutes. Mice were treated with the hepatotoxin CCl₄ 60 minutes after MB injection and sacrificed after 24 hours. (B) Hematoxylin and eosin (H&E) staining of liver sections and (C) alanine aminotransferase (ALT) activity reflecting liver injury after exposition to a US-guided burst of MB (+US, black) or without (-US, white). (D) Flow cytometric quantifications of leukocytes, (E) inflammatory macrophages and neutrophils in the liver. (F) Eight weeks old C57BL/6 mice were treated with the hepatotoxin CCl₄, followed twelve hours later by an intravenous injection of MB. Mice were exposed to a US-guided burst of

MB after seven minutes and sacrificed after twelve hours. (G) H&E staining of liver sections and (H) ALT activity measurements. (I) Leukocyte cell numbers and (J) inflammatory macrophages and neutrophils were analyzed by flow cytometry. Data represent mean $\pm$ SD ($n=3$ *per* condition), two-tailed unpaired Student *t*-test.